7DHA
| crystal structure of CD38 in complex with daratumumab | Descriptor: | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, Heavy Chain, Light chain | Authors: | Lee, H.T, Heo, Y.S. | Deposit date: | 2020-11-13 | Release date: | 2021-09-22 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.55 Å) | Cite: | Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma. Biochem.Biophys.Res.Commun., 536, 2021
|
|
7EOW
| |
5X8M
| PD-L1 in complex with durvalumab | Descriptor: | Programmed cell death 1 ligand 1, durvalumab heavy chain, durvalumab light chain | Authors: | Heo, Y.S, Lee, H.T. | Deposit date: | 2017-03-03 | Release date: | 2017-08-16 | Method: | X-RAY DIFFRACTION (2.661 Å) | Cite: | Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab Sci Rep, 7, 2017
|
|
5X8L
| PD-L1 in complex with atezolizumab | Descriptor: | Programmed cell death 1 ligand 1, atezolizumab heavy chain, atezolizumab light chain | Authors: | Heo, Y.S, Lee, H.T. | Deposit date: | 2017-03-03 | Release date: | 2017-08-16 | Method: | X-RAY DIFFRACTION (3.1 Å) | Cite: | Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab Sci Rep, 7, 2017
|
|
1ZOI
| Crystal Structure of a Stereoselective Esterase from Pseudomonas putida IFO12996 | Descriptor: | esterase | Authors: | Elmi, F, Lee, H.T, Huang, J.Y, Hsieh, Y.C, Wang, Y.L, Chen, Y.J, Shaw, S.Y, Chen, C.J. | Deposit date: | 2005-05-13 | Release date: | 2006-05-02 | Last modified: | 2024-03-13 | Method: | X-RAY DIFFRACTION (1.6 Å) | Cite: | Stereoselective esterase from Pseudomonas putida IFO12996 reveals alpha/beta hydrolase folds for D-beta-acetylthioisobutyric acid synthesis J.Bacteriol., 187, 2005
|
|
7BXA
| Crystal structure of PD-1 in complex with tislelizumab Fab | Descriptor: | Programmed cell death protein 1, heavy chain, light chain | Authors: | Heo, Y.S, Lee, S.H, Lim, H, Lee, H.T, Kim, Y.J, Park, E.B. | Deposit date: | 2020-04-18 | Release date: | 2020-06-10 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (3.32 Å) | Cite: | Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy. Biochem.Biophys.Res.Commun., 527, 2020
|
|
3JBK
| Cryo-EM reconstruction of the metavinculin-actin interface | Descriptor: | ADENOSINE-5'-DIPHOSPHATE, Actin, alpha skeletal muscle, ... | Authors: | Kim, L.Y, Thompson, P.M, Lee, H.T, Pershad, M, Campbell, S.L, Alushin, G.M. | Deposit date: | 2015-09-03 | Release date: | 2015-11-04 | Last modified: | 2024-02-21 | Method: | ELECTRON MICROSCOPY (8.2 Å) | Cite: | The Structural Basis of Actin Organization by Vinculin and Metavinculin. J.Mol.Biol., 428, 2016
|
|
3JBJ
| Cryo-EM reconstruction of F-actin | Descriptor: | ADENOSINE-5'-DIPHOSPHATE, Actin, alpha skeletal muscle, ... | Authors: | Kim, L.Y, Thompson, P.M, Lee, H.T, Pershad, M, Campbell, S.L, Alushin, G.M. | Deposit date: | 2015-09-03 | Release date: | 2015-11-04 | Last modified: | 2024-02-21 | Method: | ELECTRON MICROSCOPY (7.6 Å) | Cite: | The Structural Basis of Actin Organization by Vinculin and Metavinculin. J.Mol.Biol., 428, 2016
|
|
3JBI
| MDFF model of the vinculin tail domain bound to F-actin | Descriptor: | ADENOSINE-5'-DIPHOSPHATE, Actin, alpha skeletal muscle, ... | Authors: | Kim, L.Y, Thompson, P.M, Lee, H.T, Pershad, M, Campbell, S.L, Alushin, G.M. | Deposit date: | 2015-09-02 | Release date: | 2015-11-04 | Last modified: | 2024-02-21 | Method: | ELECTRON MICROSCOPY (8.5 Å) | Cite: | The Structural Basis of Actin Organization by Vinculin and Metavinculin. J.Mol.Biol., 428, 2016
|
|
7WWP
| Crystal structure of human Npl4 | Descriptor: | Nuclear protein localization protein 4 homolog, ZINC ION | Authors: | Nguyen, T.Q, Le, L.T.M, Kim, D.H, Ko, K.S, Lee, H.T, Nguyen, Y.T.K, Kim, H.S, Han, B.W, Kang, W, Yang, J.K. | Deposit date: | 2022-02-14 | Release date: | 2022-09-21 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.99 Å) | Cite: | Structural basis for the interaction between human Npl4 and Npl4-binding motif of human Ufd1. Structure, 30, 2022
|
|
7WWQ
| Crystal structure of human Ufd1-Npl4 complex | Descriptor: | Nuclear protein localization protein 4 homolog, Ubiquitin recognition factor in ER-associated degradation protein 1 | Authors: | Nguyen, T.Q, Le, L.T.M, Kim, D.H, Ko, K.S, Lee, H.T, Nguyen, Y.T.K, Kim, H.S, Han, B.W, Kang, W, Yang, J.K. | Deposit date: | 2022-02-14 | Release date: | 2022-09-21 | Last modified: | 2024-05-29 | Method: | X-RAY DIFFRACTION (2.72 Å) | Cite: | Structural basis for the interaction between human Npl4 and Npl4-binding motif of human Ufd1. Structure, 30, 2022
|
|
5GGU
| Crystal structure of tremelimumab Fab | Descriptor: | heavy chain, light chain | Authors: | Heo, Y.S. | Deposit date: | 2016-06-16 | Release date: | 2016-11-09 | Last modified: | 2016-11-16 | Method: | X-RAY DIFFRACTION (2.292 Å) | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy Nat Commun, 7, 2016
|
|
5GGS
| PD-1 in complex with pembrolizumab Fab | Descriptor: | Programmed cell death protein 1, heavy chain, light chain | Authors: | Heo, Y.S. | Deposit date: | 2016-06-16 | Release date: | 2016-11-09 | Last modified: | 2016-11-16 | Method: | X-RAY DIFFRACTION (1.997 Å) | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy Nat Commun, 7, 2016
|
|
5GGV
| CTLA-4 in complex with tremelimumab Fab | Descriptor: | Cytotoxic T-lymphocyte protein 4, heavy chain, light chain | Authors: | Heo, Y.S. | Deposit date: | 2016-06-16 | Release date: | 2016-11-09 | Last modified: | 2016-11-16 | Method: | X-RAY DIFFRACTION (1.998 Å) | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy Nat Commun, 7, 2016
|
|
5GGT
| PD-L1 in complex with BMS-936559 Fab | Descriptor: | IGK@ protein, IgG H chain, Programmed cell death 1 ligand 1 | Authors: | Heo, Y.S. | Deposit date: | 2016-06-16 | Release date: | 2016-11-09 | Last modified: | 2024-03-20 | Method: | X-RAY DIFFRACTION (2.8 Å) | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy Nat Commun, 7, 2016
|
|
5GGR
| PD-1 in complex with nivolumab Fab | Descriptor: | Programmed cell death protein 1, heavy chain, light chain | Authors: | Heo, Y.S. | Deposit date: | 2016-06-16 | Release date: | 2016-11-09 | Last modified: | 2016-11-16 | Method: | X-RAY DIFFRACTION (3.3 Å) | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy Nat Commun, 7, 2016
|
|
5GGQ
| Crystal structure of Nivolumab Fab fragment | Descriptor: | nivolumab heavy chain, nivolumab light chain | Authors: | Heo, Y.S. | Deposit date: | 2016-06-16 | Release date: | 2016-11-09 | Last modified: | 2016-11-16 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy Nat Commun, 7, 2016
|
|
1F5Y
| NMR STRUCTURE OF A CONCATEMER OF THE FIRST AND SECOND LIGAND-BINDING MODULES OF THE HUMAN LDL RECEPTOR | Descriptor: | CALCIUM ION, LOW-DENSITY LIPOPROTEIN RECEPTOR | Authors: | Kurniawan, N.D, Atkins, A.R, Brereton, I.M, Kroon, P.A, Smith, R. | Deposit date: | 2000-06-18 | Release date: | 2000-08-30 | Last modified: | 2022-02-16 | Method: | SOLUTION NMR | Cite: | NMR structure of a concatemer of the first and second ligand-binding modules of the human low-density lipoprotein receptor. Protein Sci., 9, 2000
|
|
6JC2
| Crystal structure of the Fab fragment of ipilimumab | Descriptor: | SULFATE ION, ipilimumab fab heavy chain, ipilimumab fab light chain | Authors: | Heo, Y.S. | Deposit date: | 2019-01-27 | Release date: | 2019-09-11 | Method: | X-RAY DIFFRACTION (2.65 Å) | Cite: | Crystal Structure of the Fab Fragment of an Anti-CTLA-4 Antibody, Ipilimumab, Used for Cancer Immunotherapy Bull.Korean Chem.Soc., 40, 2019
|
|
5Y9J
| BAFF in complex with belimumab | Descriptor: | Tumor necrosis factor ligand superfamily member 13B, belibumab light chain, belimumab heavy chain | Authors: | Heo, Y.-S, Shin, W. | Deposit date: | 2017-08-25 | Release date: | 2018-02-21 | Last modified: | 2019-09-04 | Method: | X-RAY DIFFRACTION (2.05 Å) | Cite: | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus. Nat Commun, 9, 2018
|
|
5Y9K
| Structure of the belimumab Fab fragment | Descriptor: | belimumab heavy chain, belimumab light chain | Authors: | Heo, Y.-S, Shin, W. | Deposit date: | 2017-08-25 | Release date: | 2018-02-21 | Last modified: | 2019-09-04 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus. Nat Commun, 9, 2018
|
|
2LCI
| Solution NMR Structure of DE NOVO DESIGNED PROTEIN, P-LOOP NTPASE FOLD, Northeast Structural Genomics Consortium Target OR36 (CASD Target) | Descriptor: | Protein OR36 | Authors: | Liu, G, Koga, N, Koga, R, Xiao, R, Janjua, H, Ciccosanti, C, Lee, H, Acton, T.B, Everett, J, Baker, D, Montelione, G.T, Northeast Structural Genomics Consortium (NESG) | Deposit date: | 2011-04-29 | Release date: | 2011-06-29 | Last modified: | 2024-05-15 | Method: | SOLUTION NMR | Cite: | Northeast Structural Genomics Consortium Target OR36 To be Published
|
|
7WSL
| PD-1 in complex with Dostarlimab | Descriptor: | Programmed cell death protein 1, heavy chain, light chain | Authors: | Heo, Y.S. | Deposit date: | 2022-01-30 | Release date: | 2022-08-24 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (1.534 Å) | Cite: | Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy. Biochem.Biophys.Res.Commun., 599, 2022
|
|